European Commission Approves Pfizer's TALZENNA In Combination With XTANDI For Adult Patients With Metastatic Castration-Resistant Prostate Cancer
Portfolio Pulse from Benzinga Newsdesk
The European Commission has approved Pfizer's TALZENNA in combination with XTANDI for treating adult patients with metastatic castration-resistant prostate cancer (mCRPC) where chemotherapy is not clinically indicated. This makes TALZENNA the first and only PARP inhibitor approved in the EU for use with XTANDI for mCRPC patients. The approval is based on the Phase 3 TALAPRO-2 trial results, which showed a significant reduction in disease progression or death risk. TALZENNA is also approved in the U.S. for mCRPC in combination with XTANDI.
January 08, 2024 | 3:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pfizer's TALZENNA, in combination with XTANDI, has been approved by the European Commission for mCRPC treatment, potentially increasing the drug's market and usage in the EU.
The approval of TALZENNA in the EU is likely to have a positive impact on Pfizer's stock in the short term due to the expansion of the drug's market potential and the positive trial results that support its efficacy. This regulatory milestone can lead to increased sales and market penetration in the EU, which investors may view favorably.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100